Gender clinics and the whistleblowers

What did staff at Tavistock, Amsterdam, St Louis and other clinics report from the inside?

Public debate about paediatric gender medicine often treats “the clinic” as a single, unified actor. The documentary record tells a more complicated story. At several services, staff members, former staff members and safeguarding professionals reported concerns about assessment, consent, mental-health complexity, data collection, follow-up and whether clinical disagreement could safely be voiced. These reports do not all have the same status. Some are findings in employment tribunals; some are sworn allegations; some are institutional reviews; and some are professional concerns communicated co

Background

Public debate about paediatric gender medicine often treats “the clinic” as a single, unified actor. The documentary record tells a more complicated story. At several services, staff members, former staff members and safeguarding professionals reported concerns about assessment, consent, mental-health complexity, data collection, follow-up and whether clinical disagreement could safely be voiced. These reports do not all have the same status. Some are findings in employment tribunals; some are sworn allegations; some are institutional reviews; and some are professional concerns communicated confidentially to later investigators.

The most developed record comes from England’s former Gender Identity Development Service (GIDS), run by the Tavistock and Portman NHS Foundation Trust. For years it was the sole nationally commissioned NHS service for children and young people referred for gender-related distress. Its centralised structure, rapidly rising referrals and long waiting lists created exceptional pressure. NHS England commissioned Dr Hilary Cass’s Independent Review in September 2020. GIDS subsequently closed on 31 March 2024, with new regional services becoming operational from April 2024 (NHS England, 2024).

St Louis presents a different type of case. Jamie Reed was not a prescribing clinician but a case manager at Washington University School of Medicine’s Paediatric Transgender Center at St Louis Children’s Hospital between 2018 and November 2022. Her February 2023 affidavit prompted an investigation by Missouri’s Attorney General and an internal inquiry by the university. The dispute remains important precisely because Reed’s allegations were detailed and serious, while the employer’s inquiry rejected their central claims.

Amsterdam is frequently invoked because the Amsterdam UMC gender clinic helped develop what is commonly called the Dutch protocol. It should not, however, be presented as a direct equivalent of Tavistock or St Louis. The public material reviewed for this dossier does not identify a comparable published staff whistleblower report, sworn insider affidavit or employment-tribunal finding about the Amsterdam youth service. There are patient complaints, official disclosures concerning incidents and institutional responses, but that is not the same evidential category as a staff whistleblowing case.

What the documents say

Tavistock: concern, escalation and an unsafe speaking-up culture

The Appleby employment tribunal judgment is especially significant because it is not merely an account from a campaigner. Sonia Appleby, the Trust’s safeguarding lead, made protected disclosures under the Employment Rights Act 1996. The tribunal recorded that, in early 2018, ten concerned GIDS staff had approached Dr David Bell, then a staff governor. It also found that Appleby relayed concerns about safeguarding, workload and the treatment of staff raising issues (Appleby Employment Tribunal, 2021).

The tribunal did not determine that every clinical concern was correct, nor did it rule on the efficacy of puberty blockers or hormones. It did find that Appleby had made protected disclosures and suffered detriments. Its account matters because it establishes that the problem was not confined to a later media controversy: staff concerns had entered the organisation’s governance process while GIDS was still operating.

Bell’s 2018 internal report, based on communications with staff, described concern about insufficiently thorough assessment, inexperienced staffing, weak clinical governance and an atmosphere in which questioning the prevailing approach was difficult. A Trust-commissioned review by its medical director, Dr Dinesh Sinha, followed in 2019. The subsequent Cass Review did not simply repeat Bell’s conclusions, but reached related system-level concerns: the service model was overstretched; the clinical approach had not been subject to the usual controls expected for a new model of care; and the evidence base for interventions in this population was weak (Cass Review, 2024).

Care is needed with the litigation often associated with Tavistock. In Bell v Tavistock, the High Court issued a declaration in December 2020 concerning information relevant to under-16s’ consent to puberty blockers. The Court of Appeal overturned that declaration on 17 September 2021, holding that the court should not have given that general guidance in judicial-review proceedings. The appeal judgment did not constitute a finding that the evidence base was strong, nor did it resolve the internal governance concerns later addressed by Cass (Bell v Tavistock, Court of Appeal, 2021).

St Louis: a sworn account and a disputed investigation

Reed’s affidavit alleged that the St Louis clinic adopted an affirmative model that could move vulnerable young people towards puberty blockers or cross-sex hormones without adequate assessment of coexisting mental-health problems, trauma, autism, family conflict or diagnostic uncertainty. She also alleged inadequate informed consent and instances in which parental objections were not properly respected. The affidavit was sufficiently serious for Missouri Attorney General Andrew Bailey to announce an investigation in February 2023 (Reed Affidavit, 2023; Missouri Attorney General, 2023).

Those allegations must not be reported as adjudicated fact. Washington University commissioned an internal review, which reported in April 2023 that allegations of inadequate consent, failure to address mental-health needs and patient harm were unsubstantiated. The university nevertheless said it would make improvements, including requiring written parental consent before prescribing puberty blockers or hormones. Reed publicly maintained her account after the inquiry (Washington University inquiry, 2023).

The result is an evidentially mixed record. Reed’s testimony provides a first-hand description of clinic practice and should be investigated rather than dismissed because it is politically inconvenient. But an affidavit is not a judicial finding, and an employer-led inquiry is not the same as an independent public investigation. The later passage of Missouri’s SAFE Act should also not be mistaken for proof that Reed’s particular allegations were established: legislation expresses a legislature’s policy decision, not a verdict on individual clinical files.

Amsterdam: an important contrast, not proof of immunity

Amsterdam UMC responded to the Cass Review in April 2024 by stating that many of its recommendations resembled elements already used in Dutch care: extensive diagnostics, multidisciplinary working and an exploratory phase before medical treatment. It accepted the need for more research and ongoing monitoring. In June 2026, the Dutch Health Council concluded that youth care in the Netherlands was carefully organised and that available data did not justify stopping hormone treatment, while also acknowledging limited data on unwanted effects, regret and detransition (Amsterdam UMC, 2024; Gezondheidsraad, 2026).

That is a materially different official assessment from Cass. It does not erase the wider question raised by the Dutch protocol’s international influence: whether results from a highly selected early cohort can be safely generalised to a newer, larger and clinically more heterogeneous referral population. It does mean that claims of a documented Amsterdam insider scandal should be treated as unproven unless and until primary evidence emerges.

The positions

Supporters of medical transition for adolescents argue that gender dysphoria can be severe, that delays can be distressing, and that careful individualised treatment may reduce suffering. They argue that randomised placebo-controlled trials are often impracticable or unethical in this area, and that clinical decisions should not be dictated by political campaigns. Amsterdam UMC and the Dutch Health Council both stress diagnostic assessment, multidisciplinary care and informed consent rather than a simple prescription-on-request model.

Gender-critical clinicians and advocates reply that the irreversibility of cross-sex hormones and surgery, the potential effects of puberty suppression, the changing profile of referrals and the uncertainty of long-term outcomes demand a more precautionary standard. They argue that complex distress should be explored without presuming that a medical gender pathway is the correct explanation or solution. The Cass Review’s emphasis on open exploration, systematic data collection and research protocols gives institutional weight to that concern.

A fair reading recognises that both positions claim to protect vulnerable young people. The central disagreement is over what counts as adequate evidence and how uncertainty should affect interventions with potentially lifelong consequences.

Interpretation

Beyond Gender’s interpretation is that the whistleblower record exposes a governance failure before it exposes an individual clinician’s failure. At Tavistock, staff concerns were real enough to be documented in tribunal findings, followed by an independent national review and the closure of the service. That sequence makes it unreasonable to portray all internal criticism as prejudice or hostility towards transgender people.

At St Louis, the facts do not justify declaring every allegation proven. They do justify rejecting the opposite reflex: that a former staff member’s concerns can be dismissed solely because they challenge an affirmative model. When a service treats minors whose presentations may include mental illness, trauma, neurodevelopmental conditions, sexual orientation questions and family instability, rigorous assessment and transparent outcome data are not optional extras. They are the minimum safeguards.

The Amsterdam comparison is a warning against overstatement. There is no sound gender-critical case for inventing a whistleblowing scandal where the public record does not support one. But neither should the Dutch clinic’s historic status shield its protocol from independent replication, long-term follow-up and critical scrutiny. A medical model should be judged by current evidence and current patients, not by institutional prestige.

Open questions

First, which concerns raised internally at gender clinics were investigated by genuinely independent bodies, with access to complete records, rather than by employers reviewing themselves? Secondly, how often do clinics record diagnostic uncertainty, alternative explanations for distress, discontinuation of treatment, regret, detransition and adverse effects in a way that can be independently audited?

Thirdly, what happens to staff who dissent from a dominant clinical model? The Appleby judgment shows why this matters. A service cannot learn from error if safeguarding professionals and clinicians reasonably fear reputational or professional consequences for raising concerns. Finally, countries now taking different policy paths should publish comparable prospective outcomes. Without transparent denominators, long-term follow-up and meaningful comparison groups, both reassurance and alarm will continue to outrun the evidence.

On the timeline

Episodes on this idea

Inside Europe's Transgender Medicine System with Róisín Michaux